Document:

EX-10.1

 Exhibit 10.1 

April     , 2019 
 Dear
                    : 
 As an employee of Versum
Materials, Inc. or its subsidiaries (collectively, “Versum” or the “Company”), you are aware that on April 12, 2019, Versum entered into a definitive Agreement and Plan of Merger (“Merger
Agreement”) with Merck KGaA, a German corporation with general partners (“Parent”), and EMD Performance Materials Holding, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent, under which Versum would
become a wholly-owned subsidiary of Parent (the “Proposed Transaction”). This letter agreement (the “Agreement”) replaces and supersedes any retention bonus letter agreement you may have received with respect to the
merger of Versum with Entegris, Inc., and such letter is void and shall have no further force or effect. 
 In recognition of the fact that you are a valued
member of the Versum team, we would like to offer you a retention bonus in connection with the Proposed Transaction, subject to the terms and conditions of this Agreement. The Retention Bonus (as defined below) will not be applicable in any other
circumstances or for any other future transaction, unless explicitly agreed in writing by the Company and you. The Retention Bonus will be payable to you if you remain employed by the Company or its successor (or any parent or affiliate) through the
date which is six (6) months following the Closing (as defined in Appendix A) (the “Anniversary Date”), subject to the terms and conditions set forth below. The Retention Bonus is in addition to the rights (if any) you may have
under (a) the Versum Materials, Inc. Severance Plan, subject to the terms and conditions set forth in such plan (the “Plan”); or (b) the terms of any employment agreement that may be in effect between you and the Company.

 This retention bonus is personal to you and it is a condition to your receipt of any of the amounts herein that you keep this Agreement confidential and
do not discuss this Agreement with anyone other than myself, Human Resources or our Legal Department, and in confidence, your spouse or partner, financial and/or legal advisor (except to the extent the terms of this Agreement are publicly disclosed
by the Company). 
  

	1.	 Proposed Retention Bonus 

Subject to the conditions set forth herein, the Company will make a special one-time payment to you equal to
$                 as a retention bonus (the “Retention Bonus”). The Retention Bonus (a) is subject to your execution and non-revocation of a general release of claims agreement in the form determined by the Company pertaining to certain claims you may have against the Company, its affiliates and other related parties up to and through
the date the Retention Bonus is paid (the “Release”) and (b) subject to satisfaction of clause (a), will be paid by the Company in cash (less required withholdings and deductions) on or prior to sixty (60) days following
the Anniversary Date. If your employment is terminated after the Closing but prior to the Anniversary Date by the Company or its successor (or any parent or affiliate) without Cause or by you for Good Reason (each, a “Qualifying
Termination”), the Retention Bonus payment shall become due and payable in cash on or prior to sixty (60) days following such termination of employment, subject to the execution and 

 
non-revocation of the Release. No part of the Retention Bonus will be treated as compensation paid to you for purposes of calculating your entitlement to
any retirement or other benefits provided by the Company. Any payments under the Plan will continue to be paid in accordance with the terms of the Plan. 
  

	2.	 Conditions 

Your rights with respect to the Retention Bonus, in addition to the above, are subject to the satisfaction of the following conditions: 

 

	 	(a)	 The Closing must occur on or before
                 (unless such date is extended by Versum in its sole discretion); 

 

	 	(b)	 From now until the earlier of the Anniversary Date and a Qualifying Termination, (i) you must remain an
employee of the Company or its successor (or any parent or affiliate) in good standing; (ii) you must continue to perform your duties and responsibilities as assigned by the Company or its successor (or any parent or affiliate); and
(iii) you must not have given notice of termination of your employment with the Company or its successor (or any parent or affiliate) (other than for Good Reason); 

 

	 	(c)	 You have not filed or asserted any claims on or before the relevant payment date against Versum or its
successor (or any parent or affiliate) and you have executed and delivered to the Company a valid Release within twenty-one (21) days following the Anniversary Date (or, if earlier, the statutorily
required period following the date of a Qualifying Termination) and you have not revoked such release during the seven (7) day period following your delivery of the Release; 

 

	 	(d)	 You will assist Versum in all of its efforts to complete the Proposed Transaction up to and through the
Anniversary Date (or, if earlier, through the date of a Qualifying Termination). In performing these duties, you will maintain total confidentiality with regard to the Proposed Transaction (except in the good faith performance of your duties, as
permitted by Versum with Parent) and represent Versum’s interests in completing the Proposed Transaction in a timely fashion; and 

  

	 	(e)	 You will keep confidential the existence and terms of this Agreement and will not discuss it with anyone
(including your manager or supervisor) other than myself, Human Resources, or our Legal Department, and in confidence your spouse or partner, financial and/or legal advisors (except to the extent the terms of this Agreement are publicly disclosed by
the Company). 

  

	3.	 Administration 

The Retention Bonus will be administered solely by the Vice President, Human Resources and Senior Vice President, General Counsel of the Company. 

 

	4.	 Arbitration 

Any dispute or controversy arising under, related to or in connection with this Agreement or the Retention Bonus shall be settled exclusively by arbitration
before a single arbitrator in the state in which your principal place of employment is located, in accordance with the Commercial Arbitration Rules of American Arbitration Association. The arbitrator’s decision shall be final and binding on all
parties to this Agreement and such decision may be enforced in any court having competent jurisdiction. 

  
 2 

	5.	 Assignment 

This Agreement is personal to you and may not be assigned by you. This Agreement shall inure to the benefit of and be binding upon Versum and its successors.
Versum shall require, if not otherwise required by operation of law, any successor to the business, whether direct or indirect, by purchase, merger, consolidation, acquisition of stock or otherwise, to assume and perform this Agreement in the same
manner and to the same extent as Versum would be required to perform if no such succession has taken place. 
  

	6.	 Governing Law 

This Agreement shall be governed by and construed in accordance with the law of the State of New York without reference to principles of conflict of laws. 

 

	7.	 Termination 

This Agreement shall automatically terminate on                  if the
Closing has not occurred on or before that date, unless the Company extends such termination date in its sole discretion. 
  

	8.	 Effect on Existing Employment 

This Agreement shall not be construed as giving you the right to be retained in the employ of, or in any consulting relationship to, the Company or its
successor (or any parent or affiliate). You acknowledge and understand that your employment with the Company or its successor (or any parent or affiliate) is on an “at will” basis. Except as otherwise set forth herein, your employment
agreement, if any, shall remain in full force and effect. 
  

	9.	 Interpretation 

The Company shall be empowered to make all determinations or interpretations contemplated under this Agreement, which determinations and interpretations shall
be binding and conclusive on you and the Company. 
  

	10.	 No Trust Fund 

This Agreement shall not be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company and you or any other
person. To the extent that you acquire the right to receive payments from the Company under this Agreement, such right shall be no greater than the right of any unsecured general creditor of the Company. 

 

	11.	 Amendment 

This Agreement may not be amended or modified other than by a written agreement executed by you and the Company or its successors, nor may any provision hereof
be waived other than by a writing executed by you or the Company or its successors. 

  
 3 

	12.	 Entire Agreement 

This Agreement and the documents referred to herein or delivered pursuant hereto which form a part hereof contain the entire understanding of the parties with
respect to the Retention Bonus and any other retention award related to, or payable in connection with, the Proposed Transaction. There are no restrictions, agreements, promises, representations, warranties, covenants or undertakings with respect to
the Retention Bonus and any other retention award related to, or payable in connection with, the Proposed Transaction other than those expressly set forth herein and therein. This Agreement supersedes all prior agreements and understandings between
the parties with respect to the Retention Bonus and any other retention award related to, or payable in connection with, the Proposed Transaction. 
  

	13.	 Counterparts 

This Agreement may be signed in counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the
same instrument. 
  

	14.	 Section 409A of the Code 

The Company intends that this Agreement complies with Section 409A of the Internal Revenue Code of 1986, as amended (the “Code” and such
section, “Section 409A”) to the extent that the requirements of Section 409A are applicable thereto (and not exempt pursuant to the short term deferral exception under Treas. Reg. Section 1.409A-1(b)(4) or otherwise), and the provisions of this Agreement shall be construed in a manner consistent with that intention. If the Company believes, at any time, that any payment or benefit under
this Agreement that is subject to Section 409A does not so comply, this Agreement will be interpreted or reformed in the manner necessary to achieve compliance with Section 409A. If and to the extent required to comply with
Section 409A, (a) no payment or benefit required to be paid under this Agreement on account of termination of your employment shall be made unless and until you incur a “separation from service” within the meaning of
Section 409A, (b) if you are a “specified employee,” then no payment or benefit that is payable on account of your “separation from service,” as that term is defined for purposes of Section 409A, shall be made
before the date that is six (6) months after your “separation from service” (or, if earlier, the date of your death), and (c) if the applicable deadline for you to execute (and not revoke) the applicable general Release spans two
(2) calendar years, the Retention Bonus shall be paid in the second calendar year. While the payments and benefits provided hereunder are intended to be structured in a manner to avoid the implication of any penalty taxes under
Section 409A, in no event whatsoever shall the Company or any of its affiliates be liable for any additional tax, interest, or penalties that may be imposed on you as a result of Section 409A. 

 

	15.	 Section 280G of the Code 

Notwithstanding any provision of this Agreement to the contrary, if the payments or benefits received or to be received by you are contingent on the occurrence
of a change in control (including if the payment was generated by the change in control or is made as a result of an event that is closely associated with the change in control and the event is materially related to the change in control), whether
pursuant to the terms of this Agreement or any other plan, arrangement or agreement with the Company (all such payments and benefits, being hereinafter referred to as the “Total Payments”), and such payments or benefits would be
subject to the excise tax imposed under Section 4999 of the 

  
 4 

 
Code (the “Excise Tax”), you shall receive the Total Payments and be responsible for the Excise Tax; provided, however, that you shall not receive the Total
Payments and the Total Payments shall be reduced to the Safe Harbor Amount if (x) the net amount of such Total Payments, as so reduced to the Safe Harbor Amount (and after subtracting the net amount of federal, state and local income taxes on
such reduced Total Payments) is greater than or equal to (y) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of
the Excise Tax to which you would be subject in respect of such unreduced Total Payments). The “Safe Harbor Amount” is the amount to which the Total Payments would hypothetically have to be reduced so that no portion of the Total
Payments would be subject to the Excise Tax. 
 For purposes of determining whether any of the Total Payments will be subject to the Excise Tax and the
amount of such Excise Tax, (a) all of the Total Payments shall be treated as “parachute payments” (within the meaning of Section 280G(b)(2) of the Code) unless, in the opinion of tax counsel (“Tax Counsel”)
selected by the accounting firm which was, immediately prior to the Closing, the Company’s independent auditor (the “Auditor”), such payments or benefits (in whole or in part) do not constitute parachute payments, including by
reason of Section 280G(b)(4)(A) of the Code, (b) all “excess parachute payments” within the meaning of Section 280G(b)(1) of the Code shall be treated as subject to the Excise Tax unless, in the opinion of Tax Counsel, such
excess parachute payments (in whole or in part) represent reasonable compensation for services actually rendered (within the meaning of Section 280G(b)(4)(B) of the Code) in excess of the base amount (within the meaning of
Section 280G(b)(3) of the Code) allocable to such reasonable compensation, or are otherwise not subject to the Excise Tax and (c) the value of any noncash benefits or any deferred payment or benefit shall be determined by the Auditor in
accordance with the principles of Sections 280G(d)(3) and (d)(4) of the Code. If the Auditor is prohibited by applicable law or regulation from performing the duties assigned to it hereunder, then a different auditor, acceptable to both Versum and
you, shall be selected. The fees and expenses of Tax Counsel and the Auditor shall be paid by Versum. 
 Please sign this Agreement and return it to
                 by                 . We will contact you about the timing
of execution of Exhibit A. 
 We thank you in advance for the valuable contribution which you have made and which we are sure you will continue to make to
the Company. 
  

	
	Yours truly,
	
	  

	
	ACCEPTED AND AGREED:
	
	  

	[NAME]

  
 5 

 Appendix A 

Definitions 
 For the purposes of the Agreement:

 “Cause” shall have the meaning set forth in any individual employment agreement between you and the Company or, if no
such agreement exists or such term is not defined, shall mean (i) your willful and continued failure to substantially perform your duties (other than any such failure resulting from incapacity due to physical or mental illness), after written
notice from the Company requesting such substantial performance is delivered to you, which notice identifies in reasonable detail the manner in which the Company believes you have not substantially performed your duties and provides thirty
(30) days in which to cure such failure; (ii) any act of fraud, embezzlement or theft on your part against the Company, its successor or affiliates; (iii) a conviction (or plea of nolo contendere) of a felony or any crime involving
moral turpitude; (iv) a breach of a material element of the Company’s Code of Ethics or Non-Solicitation, Non-Compete, Confidentiality and Intellectual
Property Agreement (or any successor or similar policies); or (v) any material breach of your obligations under this Agreement or any individual employment agreement, which, to the extent curable, has not been cured to the reasonable
satisfaction of the Company’s board of directors within thirty (30) days after you have been provided written notice of such breach. 

“Closing” means the closing of the Proposed Transaction as defined in the Merger Agreement, as may be amended from time to
time. 
 “Good Reason” shall have the meaning set forth in any individual employment agreement between you and the Company
or, if no such agreement exists or such term is not defined, shall mean without your consent, (i) a material reduction in your duties or responsibilities; (ii) a material reduction in your base salary or target bonus opportunity;
(iii) a change of your principal place of employment of more than fifty (50) miles from your principal place of employment immediately prior to such change; provided, however, that such event will not constitute Good Reason
unless you have provided the Company notice of the existence of a Good Reason condition no more than sixty (60) days after its initial existence and the Company has failed to remedy the condition within thirty (30) days after such notice.

 Exhibit A 

Form of Release 
 As used in this
release of claims agreement (the “Release of Claims”), the term “claims” will include all claims, covenants, warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, accounts,
attorneys’ fees, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise. Capitalized terms not otherwise defined herein shall have the meaning set forth in the letter agreement, dated as of
April     , 2019, entered into with Versum Materials, Inc. (the “Company”) (the “Retention Bonus Letter”), to which this Release of Claims is attached as an Exhibit A. 

For and in consideration of the consideration provided in the Retention Bonus Letter (collectively, the “Consideration”)
and other good and valuable consideration, I, for and on behalf of myself and my heirs, administrators, executors and assigns, effective as of the date hereof, do fully and forever release, remise and discharge the Company and its subsidiaries and
affiliates (collectively, the “Company Group”), together with their respective current and former officers, directors, partners, members, shareholders, fiduciaries, counsel, employees and agents (collectively, and with the Company
Group, the “Company Parties”) from any and all claims whatsoever up to the date hereof that I had, may have had, or now have against the Company Parties, whether known or unknown, for or by reason of any matter, cause, or thing
whatsoever, including any claim arising out of or attributable to my employment or the termination of my employment with the Company Group, whether for tort, breach of express or implied contract, intentional infliction of emotional distress,
wrongful termination, unjust dismissal, defamation, libel, or slander, or under any federal, state, or local law dealing with discrimination based on age, race, sex, national origin, handicap, religion, disability or sexual orientation. The release
of claims in this Release of Claims includes, but is not limited to, all claims arising under the Age Discrimination in Employment Act of 1967 (“ADEA”), Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act
of 1990, the Civil Rights Act of 1991, the Family and Medical Leave Act of 1993, the Employee Retirement Income Security Act of 1974, the Worker Adjustment and Retraining Notification Act of 1988 and the Equal Pay Act of 1963, each as may be amended
from time to time, and all other federal, state, and local laws, the common law, and any purported restriction on an employer’s right to terminate the employment of employees. I intend this Release of Claims to be a general release of any and
all claims to the fullest extent permissible by law and for the provisions regarding the release of claims against the Company Parties to be construed as broadly as possible, and hereby incorporate in this release similar federal, state or other
laws, all of which I also hereby expressly waive. 
 By executing this Release of Claims, I specifically release all claims relating to my
service and its termination under ADEA, a U.S. federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefit plans. 

I acknowledge and agree that by virtue of the foregoing, I have waived any relief available to me (including without limitation, monetary
damages, equitable relief and reinstatement) under any of the claims and/or causes of action waived in this Release of Claims. Therefore, I agree that I will not accept any award or settlement from the Company Group (including but not limited to any
proceeding brought by any other person or by any government agency) with respect to any claim or right waived in this Release of Claims. 

 Notwithstanding the foregoing, nothing in this Release of Claims shall be a waiver of:
(i) my rights with respect to the Consideration; (ii) my rights to benefits due to terminated employees under any pension plan (as defined in Section 3(2) of ERISA) of the Company Group, including any qualified pension plan;
(iii) my rights under my employment agreement, if any; (iv) my rights under the Plan, if any; (v) my rights to make any Permitted Disclosure (as described below) or to collect a whistleblower award from any Governmental Entity (as
defined below) arising from or in connection with any Permitted Disclosure; and (vi) any claims that cannot be waived by law including, without limitation, any claims filed with the Equal Employment Opportunity Commission, the U.S. Department
of Labor, or claims under ADEA that arise after the date of this Release of Claims. 
 Nothing in this Release of Claims shall prohibit or
impede me from communicating, cooperating or filing a complaint with any U.S. federal, state or local governmental or law enforcement branch, agency or entity (collectively, a “Governmental Entity”) with respect to possible
violations of any U.S. federal, state or local law or regulation, or otherwise making disclosures to any Governmental Entity, in each case, that are protected under the whistleblower provisions of any such law or regulation, provided that in each
case such communications and disclosures are consistent with applicable law (a “Permitted Disclosure”). I understand that I do not need the prior authorization of (or to give notice to) the Company regarding any such communication
or disclosure. I further understand and acknowledge that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made (i) in confidence to a federal,
state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made
under seal. I understand and acknowledge further that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade
secret information in the court proceeding, if the individual files any document containing the trade secret under seal and does not disclose the trade secret, except pursuant to court order. Notwithstanding the foregoing, under no circumstance will
I be authorized to disclose any information covered by attorney-client privilege or attorney work product of any member of the Company Group without prior written consent of the Company’s General Counsel or other officer designated by the
Company. 
 I expressly acknowledge and agree that I: 
  

	 	•	 	 Am able to read the language, and understand the meaning and effect, of this Release of Claims;

  

	 	•	 	 Have no physical or mental impairment of any kind that has interfered with my ability to read and understand the
meaning of this Release of Claims or its terms, and that I am not acting under the influence of any medication, drug or chemical of any type in entering into this Release of Claims; 

 

	 	•	 	 Am specifically agreeing to the terms of the release contained in this Release of Claims because the Company has
agreed to pay me the Consideration, which the Company has agreed to provide because of my agreement to accept it in full settlement of all possible claims I might have or ever had, and because of my execution of this Release of Claims;

	 	•	 	 Acknowledge that but for my execution of this Release of Claims, I would not be entitled to the Consideration;

  

	 	•	 	 Understand that, by entering into this Release of Claims, I do not waive rights or claims under ADEA that may
arise after the date I execute this Release of Claims; 

  

	 	•	 	 Had or could have until
                 (the “Review Period”), in which to review and consider this Release of Claims, and that if I execute this Release of Claims
prior to the expiration of the Review Period, I have voluntarily and knowingly waived the remainder of the Review Period; 

  

	 	•	 	 Was advised to consult with my attorney regarding the terms and effect of this Release of Claims; and

  

	 	•	 	 Have signed this Release of Claims knowingly and voluntarily. 

Notwithstanding anything contained herein to the contrary, this Release of Claims will not become effective or enforceable prior to the
expiration of the period of seven (7) calendar days following the date of its execution by me (the “Revocation Period”), during which time I may revoke my acceptance of this Release of Claims by notifying the Company, in
writing, delivered to the Company at its principal executive office, marked for the attention of its Chief Human Resources Officer. To be effective, such revocation must be received by the Company on or prior to the seventh (7th) calendar day following the execution of this Release of Claims. Provided that the Release of Claims is executed and I do not revoke it during the Revocation Period, the eighth (8th) day following the date on which this Release of Claims is executed shall be its effective date (the “Release Effective Date”). I acknowledge and agree that if I revoke this Release
of Claims during the Revocation Period, this Release of Claims will be null and void and of no effect, and neither the Company nor any other member of the Company Group will have any obligations to pay me the Consideration. 

The provisions of this Release of Claims shall be binding upon my heirs, executors, administrators, legal personal representatives, and
assigns. If any provision of this Release of Claims shall be held by any court of competent jurisdiction to be illegal, void, or unenforceable, such provision shall be of no force or effect. The illegality or unenforceability of such provision,
however, shall have no effect upon and shall not impair the enforceability of any other provision of this Release of Claims. 

 EXCEPT WHERE PREEMPTED BY FEDERAL LAW, THIS RELEASE SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH FEDERAL LAW AND THE LAWS OF THE STATE OF NEW YORK, APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN THAT STATE WITHOUT GIVING EFFECT TO THE PRINCIPLES OF CONFLICTS OF LAWS. 

 

			
	  

	[Name]
		
	Dated:EX-4.2

 Exhibit 4.2 

EXECUTION COPY 

CORTEXYME, INC. 

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 23rd day of May, 2018, by
and among Cortexyme, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and each of the
stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with
Section 6.9 hereof. 
 RECITALS 

WHEREAS, certain of the Investors (the “Existing Investors”) hold shares of the Company’s Series A Preferred
Stock and/or shares of Common Stock issued upon conversion thereof and possess registration rights, information rights, rights of first offer, and other rights pursuant to that certain Investors’ Rights Agreement dated as of December 22,
2015, by and among the Company and such Existing Investors (the “Prior Agreement”); and 
 WHEREAS, the Existing
Investors are holders of at least sixty percent (60%) of the Registrable Securities of the Company (as defined in the Prior Agreement), and desire to amend and restate the Prior Agreement in its entirety and to accept the rights created pursuant to
this Agreement in lieu of the rights granted to them under the Prior Agreement; and 
 WHEREAS, certain of the Investors are parties
to that certain Series B Preferred Stock Purchase Agreement of even date herewith by and among the Company and such Investors (the “Purchase Agreement”), under which certain of the Company’s and such Investors’ obligations
are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding at least sixty percent (60%) of the Registrable Securities, and the Company; 

NOW, THEREFORE, the Existing Investors hereby agree that the Prior Agreement shall be amended and restated, and the parties to this
Agreement further agree as follows: 
 1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly,
controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any investment fund or other pooled investment vehicle now or
hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment adviser with, such Person. 

1.2 “Common Stock” means shares of the Company’s common stock, par value $0.001 per share. 

 1.3 “Competitor” means a Person engaged directly (including
through any partnership, collaboration, joint venture or similar arrangement (whether now existing or formed hereafter)), in the research, development or commercialization of pharmaceutical, vaccine or diagnostic products targeting P.
gingivalis; provided, however, that, for the avoidance of doubt, no Investor shall be deemed to be engaged in such activities solely as a result of an investment entailing holdings of less than 20% of the outstanding equity of a
Person engaged in such activities. 
 1.4 “Damages” means any loss, damage, claim or liability (joint or
several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon:
(i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto;
(ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party
(or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable
for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.6 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.7 “Excluded Registration” means (i) a registration relating to the sale of securities to employees of
the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information
as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered. 
 1.8 “Form S-1” means such
form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.9 “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

  
 2 

 1.10 “GAAP” means generally accepted accounting principles
in the United States. 
 1.11 “Holder” means any holder of Registrable Securities who is a party to this
Agreement. 
 1.12 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent,
grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law,
brother-in-law, or sister-in-law, including, adoptive relationships, of a
natural person referred to herein. 
 1.13 “Initiating Holders” means, collectively, Holders who properly
initiate a registration request under this Agreement. 
 1.14 “IPO” means the Company’s first
underwritten public offering of its Common Stock under the Securities Act. 
 1.15 “Key Employee” means any
executive-level employee (including vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase
Agreement). 
 1.16 “Key Holder Registrable Securities” means (i) the 9,000,000 shares of Common Stock
held by the Key Holders, and (ii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in
replacement of such shares. 
 1.17 “Major Investor” means any Investor that, individually or together with
such Investor’s Affiliates, holds at least 560,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 1.20 “Preferred Director” means any director of the Company that the holders
of record of the Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation. 
 1.21
“Preferred Stock” means shares of the Company’s Preferred Stock, $0.001 par value per share. 

  
 3 

 1.22 “Registrable Securities” means (i) the Common
Stock issuable or issued upon conversion of the Preferred Stock; (ii) the Key Holder Registrable Securities, provided, however, that such Key Holder Registrable Securities shall not be deemed Registrable Securities
and the Key Holders shall not be deemed Holders for the purposes of Sections 2.1, 2.10, 3.1, 3.2, 4.1 and 6.6; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any
warrant, right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however, any Registrable
Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1, and excluding for purposes of Section 2 any shares for which registration
rights have terminated pursuant to Section 2.13 of this Agreement. 
 1.23
“Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable
(directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities. 
 1.24
“Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Section 2.12(a) hereof. 

1.25 “SEC” means the Securities and Exchange Commission. 

1.26 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act. 

1.27 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act. 

1.28 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. 
 1.29 “Selling Expenses” means all underwriting discounts, selling commissions, and stock
transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in
Section 2.6. 
 1.30 “Series A Preferred Stock” means shares of the Company’s
Series A Preferred Stock, par value $0.001 per share. 
 1.31 “Series B Preferred Stock” means shares of the
Company’s Series B Preferred Stock, par value $0.001 per share. 

  
 4 

 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date of
this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders of thirty-five percent (35%) of the Registrable Securities then
outstanding that the Company file a Form S-1 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price of at least
$10 million, then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as
practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all
Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to
the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(b) Form S-3 Demand. If at any time when it is eligible to use a Form
S-3 registration statement, the Company receives a request from Holders of at least five percent (5%) of the Registrable Securities then outstanding that the Company file a Form
S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $1 million, then the
Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days
after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration
by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Sections 2.1(c) and 2.3. 

(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its
stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a
significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential;
or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or
effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided, however, that the Company may not invoke this right more than
once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such ninety (90) day period other than an Excluded
Registration. 

  
 5 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Section 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty
(180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected two registrations pursuant to Section 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to
Section 2.1(b) (i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a
Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations
pursuant to Section 2.1(b) within the twelve (12) month period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this
Section 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration
expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration statement shall be counted as “effected” for purposes of this
Section 2.1(d). 
 2.2 Company Registration. If the Company proposes to register (including, for this purpose, a
registration effected by the Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the
Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of
Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses)
of such withdrawn registration shall be borne by the Company in accordance with Section 2.6. 
 2.3
Underwriting Requirements. 
 (a) If, pursuant to Section 2.1, the Initiating Holders intend to
distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1, and the Company shall include such
information in the Demand Notice. The underwriter(s) will be selected by the Company and shall be reasonably acceptable to a majority in interest of the 

  
 6 

 
Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in
such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as
provided in Section 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3,
if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that
otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as
nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number of Registrable Securities
held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to
Section 2.2, the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and
its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by
stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company
shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the
underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in
proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall
(i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, (ii) the number of Registrable
Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters
make the determination described above and no other stockholder’s securities are included in such offering or (iii) notwithstanding (ii) above, any Registrable Securities which are not Key Holder Registrable Securities be excluded from
such underwriting unless all Key Holder Registrable Securities are first excluded from such offering. For purposes of the provision in this Section 2.3(b) concerning apportionment, for any selling Holder that is a
partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, 

  
 7 

 
and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the
foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included
in such “selling Holder,” as defined in this sentence. 
 (c) For purposes of Section 2.1, a
registration shall not be counted as “effected” if the total number of Registrable Securities that are actually included in a registration are fewer than the total number of Registrable Securities that Holders have requested to be included
in such registration. 
 2.4 Obligations of the Company. Whenever required under this Section 2 to effect
the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the
SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of
the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or
delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to an additional sixty (60) days, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and
the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

  
 8 

 (e) in the event of any underwritten public offering, enter into and perform its
obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering; 
 (f) use its
commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which
similar securities issued by the Company are then listed; 
 (g) provide a transfer agent and registrar for all Registrable Securities
registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such
registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the
Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy
of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify each
selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and 

(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

  
 9 

 2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in
connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the
Company; and the reasonable fees and disbursements, not to exceed $35,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the
Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the
Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of
the Registrable Securities agree to forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b), as the case may be; provided further that if, at the time of such withdrawal, the Holders shall
have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such
information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Sections 2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities
registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf. 

2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any
registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling
Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who
controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this
Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the
Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 

  
 10 

 (b) To the extent permitted by law, each selling Holder, severally and not jointly, will
indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and
accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each
case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such
registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages
may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such
settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution
under Sections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 

(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of
any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate
jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other
indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the
counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to the
indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Section 2.8, to the extent that such failure
materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under this
Section 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment
or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this
Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this
Section 2.8, then, and in each such case, such parties will contribute to the aggregate losses, claims, 

  
 11 

 
damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying
party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of
the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided
further that in no event shall a Holder’s liability pursuant to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b), exceed the
proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the
termination of this Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC
Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the
Company shall: 
 (a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule
144, at all times after the effective date of the registration statement filed by the Company for the IPO; 
 (b) file with the SEC in a
timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); (ii) a copy of the most recent 

  
 12 

 
annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other information as may be reasonably requested in availing any Holder
of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 
 2.10 Limitations on Subsequent
Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of 60% of the Registrable Securities then outstanding, enter into any agreement with any holder or
prospective holder of any securities of the Company that would (i) allow such holder or prospective holder to include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include
such securities in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to
initiate a demand for registration of any securities held by such holder or prospective holder; provided that this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with
Section 6.9. 
 2.11 “Market Stand-off”
Agreement. Each Holder hereby agrees that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company of shares of its
Common Stock or any other equity securities under the Securities Act in an IPO, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days in the case of the IPO, or
such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not
limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto, provided, however, that such other period shall not exceed the maximum period required pursuant to such
rules), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or
(ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be
settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement, and shall be applicable to the Holders only if all officers, directors, and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock (after giving effect to
conversion into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions. The underwriters in connection with such registration are intended third-party beneficiaries of this
Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such 

  
 13 

 
agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to
give further effect thereto. Any discretionary waiver or termination of the restrictions of any or all of such agreements by the Company or the underwriters shall apply pro rata to all Holders subject to such agreements, based on the number of
shares subject to such agreements. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the
provisions and upon the conditions specified in this Agreement. 
 (b) Company Right of First Refusal. Before any of the Preferred
Stock or the Registrable Securities held by a Holder may be sold or otherwise transferred (including transfer by gift or operation of law) to a Competitor that is not (x) an Affiliate of such Holder or (y) another Holder (a
“Proposed Competitor Transferee”), the Company shall first have the right to purchase all or any part of the Preferred Stock or the Registrable Securities proposed to be sold or transferred in its sole and absolute discretion (the
“Company Right of First Refusal”). If a Holder would like to sell or transfer any Preferred Stock or Registrable Securities held by such Holder to a Proposed Competitor Transferee, the Holder must provide the Company or its
assignee(s) with a ROFR Notice (as defined below) requesting approval to sell or transfer such securities and offering the Company or its assignee(s) a Company Right of First Refusal on the same terms and conditions set forth in this
Section 2.12(b). The Company may either (1) exercise the Company Right of First Refusal in full or in part and purchase such securities pursuant to this Section 2.12(b) or (2) decline to exercise the Company Right of First
Refusal in full or in part and permit the transfer of such securities to the Proposed Competitor Transferee in full or in part. 
 (i)
Notice of Proposed Transfer. The Holder of the Preferred Stock or the Registrable Securities proposed to be sold or transferred to a Proposed Competitor Transferee, and therefore subject to the Company Right of First Refusal, shall deliver to
the Company a written notice (the “ROFR Notice”) stating: (A) the Holder’s intention to sell or otherwise transfer such securities; (B) the name of each Proposed Competitor Transferee; (C) the number and type of
securities to be sold or transferred to each Proposed Competitor Transferee; (D) the terms and conditions of each proposed sale or transfer, including (without limitation) the purchase price for such securities (the “Transfer Purchase
Price”); and (E) the Holder’s offer to the Company or its assignee(s) to purchase such securities at the Transfer Purchase Price and upon the same terms (or terms that are no less favorable to the Company). 

  
 14 

 (ii) Exercise of Company Right of First Refusal. At any time within 30 days after
receipt of the ROFR Notice, the Company and/or its assignee(s) shall deliver a written notice to the Holder indicating whether the Company and/or its assignee(s) elect to accept or decline the offer to purchase any or all of the securities proposed
to be sold or transferred to any one or more of the Proposed Competitor Transferees, at the Transfer Purchase Price, provided that if the Transfer Purchase Price consists of no legal consideration (as, for example, in the case of a transfer by
gift), the purchase price will be the fair market value of the securities as determined in good faith by the Company. If the Transfer Purchase Price includes consideration other than cash, the cash equivalent value of the non-cash consideration shall be determined by the Company in good faith. 
 (iii) Payment. Payment
of the Transfer Purchase Price shall be made in cash (by check) or by such other method as shall mutually be agreed to by the Company and the Holder within 60 days after receipt of the ROFR Notice or in the manner and at the times set forth in the
ROFR Notice. 
 (iv) Holder’s Right to Transfer. If any of the securities proposed in the ROFR Notice to be sold or transferred
to a given Proposed Competitor Transferee are not purchased by the Company and/or its assignee(s) as provided in this Section 2.12(b), then the Holder may sell or otherwise transfer any such securities to the applicable Proposed Competitor
Transferee at the Transfer Purchase Price or at a higher price, provided that such sale or other transfer is consummated within 120 days after the date of the ROFR Notice; provided that any such sale or other transfer is also effected in accordance
with the conditions specified in this Agreement. If the securities described in the ROFR Notice are not transferred to the Proposed Competitor Transferee within such period, or if the Holder proposes to change the price or other terms to make them
more favorable to the Proposed Competitor Transferee, a new ROFR Notice shall be given to the Company, and the Company and/or its assignees shall again have the right to approve such transfer and be offered the Company Right of First Refusal. 

(c) Termination of Company Right of First Refusal. The covenants set forth in Section 2.12(b) shall terminate
and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

(d) Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable Securities, and
(iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the
provisions of Section 2.12(e)) be notated with a legend substantially in the following form: 
 THE SECURITIES
REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 

  
 15 

 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN
AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent to
the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12. 

(e) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall
give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the
effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without
registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or
transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the
terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with SEC Rule 144; or (y) in any transaction in which such
Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.12. Each certificate,
instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in
Section 2.12(c), except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order
to establish compliance with any provisions of the Securities Act. 
 2.13 Termination of Registration Rights. The right of any
Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon: 

(a) the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation; 

  
 16 

 (b) such time as Rule 144 or another similar exemption under the Securities Act is
available for the sale of all of such Holder’s shares without limitation during a three-month period without registration; and 

(c) the fifth anniversary of the IPO. 

3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor (other than a Major Investor reasonably deemed
by the Company to be Competitor; provided, however, that in the event Pfizer Manufacturing LLC, a limited liability company organized under the laws of the State of Delaware (“PM LLC”) and
Pfizer Production LLC, a limited liability company organized under the laws of the State of Delaware (“PP LLC” and, together with PM LLC, the “General Partners”) acting in
their capacity as general partners for and on behalf of C.P. Pharmaceuticals International, C.V., a Netherlands limited partnership (commanditaire vennootschap) having its seat at Rotterdam, The Netherlands, registered with the Trade Register
held by the Chamber of Commerce of Rotterdam, the Netherlands, under number 24280998 or Pfizer Inc. (collectively, “Pfizer”) or Takeda Ventures, Inc. (“Takeda”) is or becomes a Competitor, the investment, legal,
finance, tax, accounting and audit personnel of such Investor shall continue to have access to the information rights set forth in this Section 3.1 solely for the purposes of managing, evaluating and reporting such
Investor’s investment in the Company): 
 (a) as soon as practicable, but in any event within one hundred twenty (120) days after
the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and (iii) a statement of stockholders’ equity as of the end of such year, all
such financial statements audited and certified by independent public accountants of nationally recognized standing selected by the Company; 

(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of
the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP
(except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(c) as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement and
statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal
year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(d) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next
fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any
other budgets or revised budgets prepared by the Company; 

  
 17 

 (e) such other information relating to the financial condition, business, prospects, or
corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under this Section 3.1 to provide information
(i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which
would adversely affect the attorney-client privilege between the Company and its counsel. 
 If, for any period, the Company has any
subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the
Company and all such consolidated subsidiaries.
 Notwithstanding anything else in this Section 3.1 to the
contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date sixty (60) days before the Company’s good-faith estimate of the date of filing of a
registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this
Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. 

3.2 Inspection. The Company shall permit each Major Investor (other than a Major Investor reasonably deemed by the Company to be
Competitor; provided, however, that in the event Pfizer or Takeda is or becomes a Competitor, the investment, legal, finance, tax, accounting and audit personnel of such Investor shall continue to have access to the information rights
set forth in this Section 3.2 solely for the purposes of managing, evaluating and reporting on such Investor’s investment in the Company), at such Major Investor’s expense, to visit and inspect the Company’s
properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor;
provided, however, that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential
information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

3.3 Termination of Information. The covenants set forth in Section 3.1 and
Section 3.2 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic reporting requirements of
Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

  
 18 

 3.4 Confidentiality. Each Investor agrees that such Investor will keep confidential
and will not disclose, divulge, or use for any purpose (other than to monitor, manage, evaluate, value and/or report its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement
(including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.4 by such Investor), (b) is or has been independently developed or conceived by the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the
Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants,
consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser enters into a non-disclosure agreement with the Company in a form reasonably acceptable to the Company; (iii) to any existing or prospective Affiliate, partner, member,
stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such
information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. 

4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Section 4.1 and applicable securities
laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor. A Major Investor shall be entitled to apportion the right of first offer hereby granted to it. in such
proportions as it deems appropriate, among (i) itself and (ii) its Affiliates. 
 (a) The Company shall give notice (the
“Offer Notice”) to each Major Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it
proposes to offer such New Securities. 
 (b) By notification to the Company within twenty (20) days after the Offer Notice is given,
each Major Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor
(including all shares of Common Stock then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock
of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major
Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major Investor’s failure to do likewise. 

  
 19 

 
During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in
addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common
Stock issued and held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and
held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares.
The closing of any sale pursuant to this Section 4.1(b) shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice is given and the date of initial sale of New Securities
pursuant to Section 4.1(c). 
 (c) If all New Securities referred to in the Offer Notice are not elected to be purchased or
acquired as provided in Section 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Section 4.1(b), offer and sell the remaining
unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of
the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless
first reoffered to the Major Investors in accordance with this Section 4.1. 
 (d) The right of first offer in
this Section 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of
shares of Series B Preferred Stock to Additional Purchasers pursuant to Section 1.2 of the Purchase Agreement. 
 4.2
Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation Event, as such
term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 
 5. Additional Covenants. 

5.1 Insurance. The Company shall use its commercially reasonable efforts to obtain, from financially sound and reputable insurers,
Directors and Officers liability insurance in an amount of at least $5 million, on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance policy to be maintained until
such time as the Board of Directors determines that such insurance should be discontinued. 

  
 20 

 5.2 Employee Agreements. The Company will cause (i) each person now or
hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each Key Employee to enter
into a Confidential Information and Inventions Assignment Agreement, which includes a one (1) year nonsolicitation agreement, substantially in the form attached hereto as Exhibit A. 

5.3 Employee Stock. Unless otherwise approved by the Board of Directors, including the approval of at least one Preferred
Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option
agreements, as applicable, providing for vesting of shares over a four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining
shares vesting in equal monthly installments over the following thirty-six (36) months. 
 5.4
Board Matters. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall not compensate the
Preferred Directors for their services as directors; provided, however, that the Company shall reimburse any nonemployee directors, including without limitation the Preferred Directors, for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board. 

5.5 Successor Indemnification. If the Company or any of its successors or assignees consolidates with or merges into any other Person
and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with
respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may
be. 
 5.6 Scientific Advisory Board. The Company shall cause to be established and will maintain, a Scientific Advisory Board.
Pfizer shall be entitled to designate one member of the Scientific Advisory Board, subject to the Company’s reasonable determination that Pfizer is not a Competitor. 

5.7 Board Committees. Each committee of the Board of Directors shall, at Pfizer’s option, include the Preferred Director
designated by Pfizer pursuant to Section 1.2(a) of the Voting Agreement dated on or about the date hereof by and among the Company, the Investors, and the other parties set forth therein (the “Voting Agreement”), subject to the
Company’s reasonable determination that Pfizer is not a Competitor.
 5.8 FCPA Compliance. The Company shall not, and shall not
permit any of its subsidiaries and Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents (collectively, “Representatives”) to, promise, authorize or
make any payment to, or otherwise contribute any item of value to, 

  
 21 

 
directly or indirectly, any non-U.S. government official, in each case, in violation of the U.S. Foreign Corrupt Practices Act (“FCPA”) or
any other applicable anti-bribery or anti-corruption law. The Company shall, and shall cause each of its subsidiaries and Affiliates to, cease all of its or their respective activities, as well as remediate any actions taken by the Company, its
subsidiaries or Affiliates or any of its or their respective Representatives in violation of the FCPA or any other applicable anti-bribery or anti-corruption law. The Company shall, and shall cause each of its Affiliates and subsidiaries to,
maintain systems or internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law. 

5.9 Termination of Covenants. The covenants set forth in this Section 5, except for
Section 5.5, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s
Certificate of Incorporation, whichever event occurs first. 
 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder
to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members;
or (iii) after such transfer, holds at least 50,000 shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company
is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in
a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11. For the purposes of determining the number of shares of Registrable Securities
held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such
Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to
the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. The validity, interpretation, construction and performance of this Agreement, and all acts and transactions pursuant
hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the state of California, without giving effect to principles of conflicts of law. 

  
 22 

 6.3 Counterparts. This Agreement may be executed in two (2) or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with
the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. 

(a) All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given
upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business
hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit
with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their
addresses as set forth on Schedule A or Schedule B (as applicable) hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or
address as subsequently modified by written notice given in accordance with this Section 6.5. If notice is given to the Company, a copy shall also be sent to Scott M. Iyama, Orrick, Herrington & Sutcliffe LLP, 1000 Marsh Road, Menlo
Park California 94025 and if notice is given to Stockholders, a copy shall also be given to Todd Carpenter, Latham & Watkins LLP, 505 Montgomery Street, Suite 2000, San Francisco, CA 94111. 

(b) Consent to Electronic Notice. Each Investor and Key Holder consents to the delivery of any stockholder notice pursuant to the
Delaware General Corporation Law (the “DGCL”), as amended or superseded from time to time, by electronic transmission pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address or the
facsimile number set forth below such Investor’s or Key Holder’s name on the Schedules hereto, as updated from time to time by notice to the Company, or as on the books of the Company. To the extent that any notice given by means of
electronic transmission is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address has been provided, and such attempted Electronic Notice shall be
ineffective and deemed to not have been given. Each Investor and Key Holder agrees to promptly notify the Company of any change in such stockholder’s electronic mail address, and that failure to do so shall not affect the foregoing. 

  
 23 

 6.6 Amendments and Waivers. Any term of this Agreement may be amended and the
observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company and the holders of at least 60% of the Registrable
Securities then outstanding; provided that the Company may in its sole discretion waive compliance with Section 2.12(e) (and the Company’s failure to object promptly in writing after notification of a proposed assignment
allegedly in violation of Section 2.12(e) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other party.
Notwithstanding the foregoing, (i) this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment,
termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the
same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction), (ii) the provisions of Section 1.3,
Section 3.1, Section 3.2, Section 5.6, and Section 5.7 may not be amended or terminated and the observance of any term thereof may not be waived
in a manner that is adverse to Pfizer without the prior written consent of Pfizer, (iii) the provisions of Section 1.3, Section 3.1, Section 3.2 and
Section 5.7 may not be amended or terminated and the observance of any term thereof may not be waived in a manner that is adverse to Takeda without the prior written consent of Takeda. The Company shall give prompt notice
of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this
Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more
instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision. 
 6.7
Severability. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other
provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 

6.8 Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the
purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate. 

6.9 Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares of the
Company’s Series B Preferred Stock after the date hereof, any purchaser of such shares of Series B Preferred Stock may become a party to this Agreement by executing and delivering an additional counterpart signature page to this Agreement, and
thereafter shall be deemed an “Investor” for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional Investor, so long as such additional Investor has agreed in
writing to be bound by all of the obligations as an “Investor” hereunder. 

  
 24 

 6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto)
constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly
canceled. Upon the effectiveness of this Agreement, the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. The Investors that are Major
Investors (as such term is defined in the Prior Agreement), on behalf of themselves and all Major Investors (as such term is defined in the Prior Agreement), hereby waive the right of first offer, including any notice requirements, set forth in
Section 4 of the Prior Agreement with respect to the issuance by the Company of Series B Preferred Stock pursuant to the Purchase Agreement and the shares of Common Stock issuable upon the conversion thereof. 

6.11 Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon
any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or
to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law
or otherwise afforded to any party, shall be cumulative and not alternative. 
 6.12 Other Business Activities of Investors. The
Company acknowledges that the Investors are in the business of investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete
directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services
which compete with those of the Company. The Company and each Investor that is a party to this Agreement, acknowledges and agrees that certain of the Investors or their Affiliates may presently have, or may engage in the future, in internal
development programs, or may receive information from third parties that relates to, and may develop and commercialize products independently or in cooperation with such third parties, that are similar to or that are directly or indirectly
competitive with, the Company’s development programs, products or services. Nothing in this Agreement or any other agreement related to the transactions contemplated by this Agreement, shall in any way preclude or restrict such Investors or
their Affiliates from conducting any development program, commercializing any product or service or otherwise engaging in any enterprise, whether or not such development program, product, service or enterprise, competes with those of the Company, so
long as such activities do not result in a violation of the confidentiality provisions of this Agreement. 
 [Remainder of Page Intentionally
Left Blank] 

  
 25 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	CORTEXYME, INC.
		
	By:	 	 /s/ Casey Lynch

	Name:	 	Casey Lynch
	Title:	 	Chief Executive Officer

 
			
	
	Address:
	
	KEY HOLDERS:
	
	CASEY LYNCH

 
			
		
	Signature:	 	 /s/ Casey Lynch

 
			
	
	STEPHEN DOMINY

 
			
		
	Signature:	 	 /s/ Stephen Dominy

			
	
	KRISTEN GAFRIC

 
			
		
	Signature:	 	 /s/ Kristen Gafric

 SIGNATURE PAGE TO CORTEXYME,
INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
 INVESTORS: 

SEQUOIA CAPITAL U.S. GROWTH FUND VII, L.P. 
 SEQUOIA CAPITAL U.S.
GROWTH VII PRINCIPALS FUND, L.P. 
 Each a Cayman Islands exempted limited partnership 

 

			
	By:	 	SC U.S. GROWTH VII MANAGEMENT, L.P.,
a Cayman Islands exempted limited partnership
General Partner of Each

By: SC US (TTGP), LTD., 
        a
Cayman Islands exempted company, its General Partner 
  

			
	By:	 	 /s/ Michael Dixon

			
	Name:	 	Michael Dixon
	Title:	 	Authorized Signatory

 Address: 

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	SMALLCAP WORLD FUND, INC.
	
	By: Capital Research and Management Company, for and on behalf of SMALLCAP World Fund, Inc.
		
	By:	 	 /s/ Kristine M. Nishiyama

	Name:	 	Kristine M. Nishiyama
	Title:	 	Authorized Signatory
		
	Address:	 	
	
	
	
	
	Email:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
 INVESTORS: 

For and behalf of: C.P. Pharmaceuticals International C.V. 
  

							
	Pfizer Manufacturing LLC,	  	Pfizer Production LLC,
	as general partner for and on behalf of	  	as general partner for and on behalf of
	C.P. Pharmaceuticals International C.V.	  	C.P. Pharmaceuticals International C.V.
				
	 By:
	  	 /s/ Brian
McMahon                                    
	  	 By:
	  	 /s/ Colum Lane

		  	 Name: Brian McMahon
	  		  	 Name: Colum Lane

		  	 Title: Senior Vice President
	  		  	 Title: Senior Vice President

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	TAKEDA VENTURES, INC.
		
	By	 	 /s/ Michael Martin

		 	Michael Martin
		 	President

 
			
		
	Address:	 	
		 	
		 	
		 	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	DOLBY FAMILY VENTURES, L.P.
		
	By:	 	 /s/ David Dolby

	Name: David Dolby
	Title: Managing Director
	
	Address:
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	THE RAY DOLBY 2002 TRUST B, DATED APRIL 19, 2002 
		
	By:	 	 /s/ David Dolby

	Name: David Dolby
	 Title: Trustee of the Ray Dolby 2002 Trust B,

Dated April 19, 2002

	
	Address:
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	PIERRE R. AND CHRISTINE E. LAMOND TRUST 11-22-85
		
	By:	 	 /s/ Pierre Lamond

	Name: Pierre Lamond
		 	(print)
	Title: Trustee

  

			
	Address:	 	  

	  

	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	BLUE DEVIL TRUST DATED 12/03/2010
		
	By:	 	 /s/ David Lamond

	Name: David Lamond
	(print)
	Title: Trustee

  

			
	Address:	 	  

	  

	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

	
	INVESTORS:
	
	ROGER QUY
	
	 /s/ Roger Quy

	
	Address:
	
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	BREAKOUT VENTURES, L.P.
	
	By: Breakout Ventures Associates LLC,
a Delaware limited liability company
	Its: General Partner

 
			
		
	By:	 	 /s/ Lindy Fishburne

			
	Name: Lindy Fishburne
	Title: Managing Member
	
	Address:
	
	
	
	
	
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

 

			
	INVESTORS:
	
	PFIZER STRATEGIC INVESTMENT HOLDINGS LLC 

 
			
		
	By:	 	 /s/ Margaret McLoughlin

			
	(Signature)
	Name: Margaret McLouglin
	Title: Executive Director
	
	Address:
	
	
	
	
	Email:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	PFIZER INC.
		
	By:	 	 /s/ Barbara Dalton

	(Signature)
	Name: Barbara Dalton
	Title: Vice President Pfizer Ventures

  

			
	Address:	 	
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	COUGAR INVESTMENT HOLDINGS LLC 
		
	By:	 	 /s/ Susan Drake

	Name: Susan Drake
	Title: Vice President
	
	Address:
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

	
	INVESTORS:
	
	ALBERT HWANG 
	
	 /s/ Albert Hwang

	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	VERILY LIFE SCIENCES LLC 
		
	By:	 	/s/ Andrew Conrad
	Name: Andrew Conrad
	Title: Chief Executive Officer
	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	THE PETER H. HUIZENGA TRUST 
		
	By:	 	/s/ Heidi A. Huizenga
	Name: Heidi A. Huizenga
	Title: Trustee
	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 THE HEIDI A. HUIZENGA TRUST 

		
	By:	 	/s/ Heidi A. Huizenga
	 Name: Heidi A. Huizenga

	 Title: Trustee

	
	 Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 HUIZENGA INVESTMENT PARTNERSHIP 

		
	By:	 	/s/ Peter H. Huizenga, Jr.
	 Name: Peter H. Huizenga, Jr.

	 Title: Executive Vice President

	
	 Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 HCM G4 INVESTMENTS, LLC 

		
	By:	 	/s/ Peter H. Huizenga, Jr.
	 Name: Peter H. Huizenga, Jr.

	 Title: Manager

	
	 Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

	
	
	INVESTORS:
	
	PETER H. HUIZENGA, JR. 
	
	 /s/ Peter H. Huizenga, Jr.

	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

	
	
	INVESTORS:
	
	DAVID A. BRADLEY 
	
	 /s/ David A. Bradley

	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	H. BARTON CO-INVEST FUND III, LLC 
		
	By:	 	H. Barton Asset Management, LLC
	Its:	 	Managing Member

 
			
		
	By:	 	 /s/ Harris Barton

	Name:	 	Harris Barton
	Title:	 	Managing Member
	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	THE KENNETH F. AND ROBBIN R. MORGAN FAMILY TRUST DATED 6/26/2007 

 
			
		
	By:	 	 /s/ Robbin Morgan

 

			
	Name:	 	Robbin Morgan

 
			
	Title:	 	Co-Trustee

 
			
		
	By:	 	 /s/ Kenneth Morgan

			
	Name:	 	Kenneth Morgan
	Title:	 	Co-Trustee
	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	THE MORGAN CHILDREN’S 2012 TRUST 

 
			
		
	By:	 	 /s/ Robbin Morgan

 

			
	Name:	 	Robbin Morgan
	Title:	 	Co-Trustee

 
			
		
	By:	 	 /s/ Kenneth Morgan

			
	Name:	 	Kenneth Morgan
	Title:	 	Co-Trustee
	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 CTEPQ PARTNERS, LLC

	 EPIQ CAPITAL GROUP 

		
	By:	 	 /s/ David Boyer

	 Name:
	 	 David Boyer

	 Title:
	 	 Chief Financial Officer

	
	 Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	ERIK T. ENGELSON, TRUSTEE OF THE ERIK T. ENGELSON TRUST UDT, DATED MARCH 29, 2000 
		
	By:	 	 /s/ Erik T. Engelson

	Name:	 	Erik T. Engelson
	Title:	 	Trustee
	
	Address:

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	FOUNDRY SQUARE INVESTORS – XVIII, LLC
		
	By:	 	 /s/ Scott Iyama

	Name:	 	Scott Iyama
	Title:	 	Authorized Signatory
	
	Address:
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	CANARAS, LLC 
		
	By:	 	 /s/ Sanford I. Weill

	Name:	 	Sanford I. Weill
	Title:	 	Manager

 
			
	
	Address:
	 

    

	
	
	Email:
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 JOHN F. HARRIS 1987 REVOCABLE TRUST 

		
	 By:
	 	 /s/ John F. Harris

	 Name:
	 	 John F. Harris

	 Title:
	 	 Trustee

	
	 Address:

	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 WILMOT VENTURES, L.P. – SERIES A

		
	By:	 	/s/ Daniel Lurie
	Name: Daniel Lurie
	 Title: General Partner

	
	 Address:

	 

    

	
	 Email: 

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

	
	 INVESTORS:

	
	 ANDREW FIRLIK

	
	 /s/ Andrew Firlik

	
	 Address:

	
	
	
	 Email: 

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	 INVESTORS:

	
	 JULIE ANN WRIGLEY 1999 REVOCABLE TRUST 

		
	 By:
	 	 /s/ Julie Ann Wrigley

	 Name: Julie Ann Wrigley

	 Title: Trustee

	
	 Address:

	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	
	 INVESTORS:

	
	 RSL INVESTMENTS II CORPORATION 

		
	 By:
	 	 /s/ Jacqueline Scalisi

	 Name: Jacqueline Scalisi

	 Title: Vice President and Secretary

	
	 Address:

	
	
	
	
	
	 Email: 

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	
	 INVESTORS:

	
	 THE BOEDING FAMILY TRUST

 
			
		
	 By:
	 	 /s/ Chad
Boeding

 
			
	Name:	 	Chad Boeding
	Title:	 	Trustee

 
			
	
	 Address:

	
	
	 Email: 

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	MICHAEL W. CLARK AND COLLEEN M. FERGUSON 
		
	By:	 	 /s/ Michael W. Clark

	Name: Michael W. Clark
	Title: Investor
		
	By:	 	 /s/ Colleen M. Ferguson

	Name: Colleen M. Ferguson
	Title: Investor
	
	Address:
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	STEPHEN L. DUNNE AND LACEY CALAC 
	 DUNNE, TRUSTEES OF THE DUNNE
 FAMILY

	TRUST CREATED JUNE 26, 2009 
		
	By:	 	 /s/ Lacey C. Dunne

	Name: Lacey C. Dunne
	Title: Trustee
	
	Address:
	Email: 

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

	
	INVESTORS:
	
	FRED COUPLES 
	
	 /s/ Fred Couples

	
	Address:
	
	
	
	Email: 
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	THE THIEL FOUNDATION 
	
	 /s/ Blake Masters

	Name:	 	Blake Masters
	Title:	 	President
	
	Address:
	
	
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	INVESTORS:
	
	PFIZER VENTURES (US) LLC 
		
	By:	 	 /s/ Andrew J. Muratore

	Name: Andrew J. Muratore
	Title: Vice President

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of date first written above. 
  
  

			
	KEY HOLDERS :
	
	 STEPHEN S. DOMINY AND YLVA K. DOMINY, TRUSTEES OF THE DOMINY

FAMILY TRUST 2016

		
	By:	 	 /s/ Stephen S. Dominy

		 	Stephen S. Dominy, Trustee
		
	By:	 	 /s/ Ylva K. Dominy

		 	    Ylva K. Dominy, Trustee
	
	Address:
	
	
	
	Email:
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	KEY HOLDERS :
	
	 ZACHARY J. LYNCH AND CASEY C.

LYNCH, TRUSTEES OF THE ZACHARY
 AND CASEY LYNCH LIVING TRUST

DATED FEBRUARY 24, 2009

		
	By:	 	 /s/ Zachary J. Lynch

		 	Zachary J. Lynch, Trustee
		
	By:	 	 /s/ Casey C. Lynch

		 	     Casey C. Lynch, Trustee
	
	Address:
	
	
	
	Email:
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	KEY HOLDERS :
	
	 MATTHEW PARKER MAHONEY, AS
 TRUSTEE
OF THE KYLE CRAWFORD
 LYNCH 2016 IRREVOCABLE TRUST
 DATED
SEPTEMBER 5, 2016

		
	By:	 	 /s/ Matthew Parker Mahoney

		 	Matthew Parker Mahoney, Trustee
	
	Address:
	
	
	
	Email:
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the date first written above. 
  
  

			
	KEY HOLDERS :
	
	MATTHEW PARKER MAHONEY, AS TRUSTEE OF THE BECKETT CRAWFORD LYNCH 2016 IRREVOCABLE TRUST DATED SEPTEMBER 5, 2016
		
	By:	 	 /s/ Matthew Parker Mahoney

		 	Matthew Parker Mahoney, Trustee
	
	Address:
	
	
	
	Email:
	

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 10, 2018. 
  
  

			
	KEY HOLDERS :
	
	BERNICE LYNCH BAJADA
		
	By:	 	 /s/ Bernice Lynch Bajada

	
	Address:
	
	
	Email:                      

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 11, 2018. 
  
  

			
	KEY HOLDERS :
	
	CHRISTOPHER LYNCH
		
	By:	 	 /s/ Christopher Lynch

	
	Address:
	
	
	Email:                      

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of the December 12, 2018. 
  
  

			
	KEY HOLDERS :
	
	DAVID W. CRAWFORD AND MEKA D. CRAWFORD, CO-TRUSTEES OF THE CRAWFORD FAMILY TRUST DATED FEBRUARY 25, 2012
		
	By:	 	 /s/ David W. Crawford

		 	(Signature)
		
	Name:	 	David W. Crawford
	Title:	 	Trustee
		
	By:	 	 /s/ Meka D. Crawford

		 	(Signature)
	Name:	 	Meka D. Crawford
	Title:	 	Trustee
	
	 Address:

	Email:	 	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 12, 2018. 
  
  

			
	KEY HOLDERS :
	
	DANIEL LYNCH

 
			
		
	By:	 	 /s/ Daniel Lynch

 
			
	
	Address:
	
	
	Email:	 	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 11, 2018. 
  
  

			
	KEY HOLDERS :
	
	JULIE LYNCH-SASSON

 
			
		
	By:	 	 /s/ Julie Lynch-Sasson

			
	
	Address:
	
	
	Email:	 	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 10, 2018. 
  
  

 

			
	KEY HOLDERS :
	
	KATHERINE LYNCH
		
	By:	 	 /s/ Katherine Lynch

			
	
	Address:
	
	

 
			
	Email:	 	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 10, 2018. 
  
  

			
	 KEY HOLDERS :

	
	KIRA LYNCH

 
			
		
	By:	 	 /s/ Kira Lynch

 
			
	
	 Address:

	
	

 
			
	 Email:
	 	  

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 21, 2018. 
  
  

			
	KEY HOLDERS :
	
	MATTHEW MAHONEY
		
	By:	 	 /s/ Matthew Mahoney

	
	Address:
	
	
	Email:	 	                        

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 10, 2018. 
  
  

			
	KEY HOLDERS :
	
	MICHAEL LYNCH
		
	By:	 	 /s/ Michael Lynch

	
	Address:
	Email:                         

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated Investors’
Rights Agreement as of December 10, 2018. 
  
  

			
	KEY HOLDERS :
	
	ROY PATRICK CRAWFORD & GAIL JOHNSTON CRAWFORD TTEE, U/A DTD JUL 19, 2000 CRAWFORD FAMILY TRUST
		
	By:	 	 /s/ Roy Patrick Crawford

	Name:	 	Roy Patrick Crawford
	Title:	 	Trustee
		
	By:	 	 /s/ Gail Johnston Crawford

	Name:	 	Gail Johnston Crawford
	Title:	 	Trustee
	
	Address:
	
	
	Email:	 	                        

  

SIGNATURE PAGE TO CORTEXYME, INC. AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Investors 
  

	
	Name and Address

 Pfizer Manufacturing LLC and Pfizer Production LLC, acting as 

general partners for and on behalf of C.P. Pharmaceuticals 

International C.V. 
 Takeda Ventures, Inc. 

 
 Pierre R. and Christine E. Lamond Trust 11-22-85 
 Robert M and Jane M. Dominy 

Scott Steward 
 Corinna Gamez 

Robert Estella 

 I.T. Invest (Ltd.) 

Roger & LaRae Quy 
 Dolby Family Ventures, L.P. 

David Lamond 
 Gillian Sandler 

The Thiel Foundation 
 Blue Devil Trust dated 12/03/2010 

Pfizer Strategic Investment Holdings LLC 
 Pfizer Inc. 

Sequoia Capital U.S. Growth Fund VII, L.P. 
 Sequoia Capital U.S.
Growth VII Principals Fund, L.P. 
 SMALLCAP World Fund, Inc. 

c/o Capital Research and Management Company 

 Breakout Ventures, L.P. 

The Ray Dolby 2002 Trust B, dated April 19, 2002 
 Cougar
Investment Holdings LLC 
 Albert Hwang 
 Verily Life Sciences
LLC 
 The Peter H. Huizenga Trust 
 The Heidi A. Huizenga
Trust 

 Huizenga Investment Partnership 

HCM G4 Investments, LLC 
 Peter H. Huizenga, Jr. 

David A. Bradley 
 H. Barton
Co-Invest Fund III, LLC 
 The Kenneth F. And Robbin R. Morgan Family Trust dated 6/26/2007 

The Morgan Children’s 2012 Trust 
 CTEPQ Partners, LLC 

EPIQ Capital Group 
 Erik T. Engelson, Trustee of the Erik T.
Engelson Trust UDT, dated March 29, 2000 

 Foundry Square Investors – XVIII, LLC 

Canaras, LLC 
 John F. Harris 1987 Revocable Trust 

Wilmot Ventures, L.P.—Series A 
 Andrew Firlik 

Julie Ann Wrigley 1999 Revocable Trust 
 RSL Investments II
Corporation 
 The Boeding Family Trust 
 Roger Quy 

 Michael W. Clark and Colleen M. Ferguson 

Stephen L. Dunne and Lacey Calac 
 Dunne, trustees of the Dunne
Family 
 Trust created June 26, 2009 
 Fred Couples 

 SCHEDULE B 

Key Holders 
 Stephen S. Dominy and Ylva
K. Dominy, Trustees of the Dominy Family Trust 2016 
 Zachary J. Lynch and Casey C. Lynch, Trustees of the Zachary and Casey Lynch Living Trust dated
February 24, 2009, and any amendments thereto 
 Matthew Parker Mahoney, as Trustee of the Kyle Crawford Lynch 2016 Irrevocable Trust dated
September 5, 2016 
 Matthew Parker Mahoney, as Trustee of the Beckett Crawford Lynch 2016 Irrevocable Trust dated September 5, 2016 

Michael Lynch 
 Kira Lynch 

Katherine Lynch 
 Roy Patrick Crawford & Gail Johnston
Crawford TTEE, U/A Dtd Jul 19, 2000 Crawford Family Trust 
 Bernice Lynch Bajada 

Julie Lynch-Sasson 
 Christopher Lynch 

Daniel Lynch 
 David W. Crawford and Meka D. Crawford, Co-Trustees of the Crawford Family Trust dated February 25, 2012 
 Matthew Mahoney 

 EXHIBIT A 

Form of Confidential Information and Inventions Assignment Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]